Watson agrees to buy portfolio of drugs due to be divested on Teva-Barr merger
The USA's Watson Pharmaceuticals has entered a definitive agreement to acquire a portfolio of generic drugs that are being divested as a result of the proposed merger between Israel's Teva Pharmaceutical Industries and Barr Pharmaceuticals. The closing of the product acquisition is contingent upon the consummation of the acquisition. The portfolio of products consists of 17 products, including 15 US-approved agents and two that are in development. The package includes: cyclosporine capsules, liquid desmopressin acetate tablets, glipizide/metformin HCl and mirtazapine. The chief executive of Watson, Paul Bisaro, said "we anticipate these new generics will have immediate value that we will begin to realize in early 2009."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze